Female Infertility | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2018
MARKET OUTLOOK
Female infertility is typically defined as the inability to achieve pregnancy after one year of attempting conception. A wide range of factors may cause female infertility, such as age, obesity, type 2 diabetes, and endometriosis. As such, there are numerous avenues to help these patients successfully conceive, including pharmacologic agents such as clomiphene citrate and follicle-stimulating hormone (e.g., Merck KGaA’s Gonal F), as well as assisted reproductive technologies including in vitro fertilization. Thus, patient-specific considerations are often needed to determine the optimal plan for initiation of treatment. Pipeline agents (e.g., ObsEva’s nolasiban) are seeking to capitalize on unmet need for improving pregnancy rates, particularly for patients undergoing assisted reproductive technology-based procedures.
QUESTIONS ANSWERED
- How large is the prevalent population of females patients suffering from infertility?
- What are the most common causes of female infertility? Is this expected to change in the next 10 years?
- What are current treatment options for female infertility? How do reproductive endocrinologists approach different underlying causes of female infertility?
- What unmet needs remain for the treatment of different drivers of infertility?
- What are the most promising pipeline agents? How do experts believe these will fit into future treatment paradigms?
PRODUCT DESCRIPTION
Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
RELEASE DATE
July 2018
GEOGRAPHIES
United States and EU5
PRIMARY RESEARCH
- Six country-specific interviews with thought-leading reproductive endocrinologists
- Supported by survey data collected for this study
EPIDEMIOLOGY
Total, diagnosed, and drug-treated prevalent cases of female infertility by country, total prevalent cases by etiology, number of procedures due to female infertility
FORECAST
Drug-level sales and patient share of key female infertility therapies in 2027
EMERGING THERAPIES
Phase III/PR: 1 drugs. Phase II: 2 drugs. Coverage of select preclinical and Phase I products.
